Bispecific antibody approved in Europe for DLBCL
European Pharmaceutical Review
JULY 11, 2023
This news follows the US Food and Drug Administration (FDA)’s approval of the anti-cancer treatment last month. The EC’s decision for Roche’s Columvi is indicated for adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
Let's personalize your content